Blueprint’s Ayvakit fails to best Bayer’s Stivarga
The firm said based on the data it would not be pursuing further development of the drug in GIST beyond its approved indication
Read More
Tag: GIST
Bayer’s Stivarga wins NICE approval for GIST
Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with gastrointestinal stromal tumours (GIST).
Read More
NICE backing for Bayer’s Stivarga in GIST
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
